Compare REAL & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | VNDA |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 474.0M |
| IPO Year | 2019 | 2005 |
| Metric | REAL | VNDA |
|---|---|---|
| Price | $9.32 | $7.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $17.00 | $14.90 |
| AVG Volume (30 Days) | 3.5M | ★ 3.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $692,845,000.00 | $216,105,000.00 |
| Revenue This Year | $14.30 | $21.35 |
| Revenue Next Year | $10.19 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | 8.72 |
| 52 Week Low | $4.61 | $3.81 |
| 52 Week High | $17.39 | $9.91 |
| Indicator | REAL | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 34.66 | 38.72 |
| Support Level | $7.21 | $4.36 |
| Resistance Level | $11.48 | $8.29 |
| Average True Range (ATR) | 0.57 | 0.58 |
| MACD | -0.07 | -0.21 |
| Stochastic Oscillator | 19.06 | 8.17 |
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.